此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

测试将抗癌药物 BAY 1895344 添加到晚期实体瘤的常规化疗中,特别关注小细胞肺癌、低分化神经内分泌癌和胰腺癌患者

2026年11月11日 更新者:National Cancer Institute (NCI)

BAY 1895344 Plus Topoisomerase-1 (Top1) 抑制剂用于晚期实体瘤患者,I 期扩展队列研究小细胞肺癌 (SCLC)、低分化神经内分泌癌 (PD-NEC) 和胰腺癌 (PDA)

This phase I trial tests the safety, side effects and best dose of BAY 1895344 when given together with usual chemotherapy (irinotecan or topotecan) in treating patients with solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced), with a specific focus on small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. BAY 1895344 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as irinotecan and topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding BAY 1895344 to irinotecan or topotecan may be safe and tolerable in treating patients with advanced solid tumors.

研究概览

详细说明

PRIMARY OBJECTIVES:

I. To assess safety and tolerability of each of the elimusertib (BAY 1895344) plus topoisomerase 1 (top1) inhibitor (irinotecan hydrochloride [irinotecan] or topotecan hydrochloride [topotecan]) combinations.

II. To estimate maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of each of the combinations.

SECONDARY OBJECTIVES:

I. To observe and record anti-tumor activity. II. To estimate objective response rate (ORR), progression free survival (PFS), overall survival (OS) and duration of response (DOR) in patients treated with each combination.

III. To estimate plasma pharmacokinetic (PK) characteristics of BAY 1895344 plus each top1 inhibitor (irinotecan or topotecan) when used in combination.

IV. To estimate changes in pharmacodynamic (PD) markers of deoxyribonucleic acid (DNA) damage (gamma-H2AX, phosphorylated [p]S343-NBS1) elicited by each combination from on-treatment tumor biopsies (in dose expansion cohorts only).

EXPLORATORY OBJECTIVES:

I. To estimate response outcomes (ORR, PFS, OS, DOR) in study patients by tumor ataxia telangiectasia mutated (ATM) expression loss (assessed by immunohistochemistry [IHC]).

II. To estimate response outcomes (ORR, PFS, OS, DOR) in study patients with tumor DNA damage response (DDR) mutations (assessed by whole exome sequencing [WES], ribonucleic acid [RNA] sequencing [RNA Seq], and circulating tumor DNA [ctDNA] analysis).

OUTLINE: This is a dose-escalation study. Patients are assigned to 1 of 3 cohorts.

COHORT I: Patients receive elimusertib orally (PO) twice daily (BID) on days 1 and 2 and irinotecan intravenously (IV) over 90 minutes on day 1 of each cycle. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) and/or magnetic resonance imaging (MRI) throughout the study, tumor biopsy at screening and on study, and collection of blood samples at screening.

COHORT II: Patients receive elimusertib PO once daily (QD) on days 2, 3, 9, 10, 16, and 17 of cycle 1 and 2, and on days 2, 3, 9, and 10 of each cycle thereafter. Patients receive irinotecan IV over 90 minutes on days 1, 8, and 15 of cycle 1 and 2, and on days 1 and 8 of each cycle thereafter. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT and/or MRI throughout the study, tumor biopsy at screening and on study, and collection of blood samples at screening.

COHORT III: Patients receive elimusertib PO QD on days 2 and 5 and topotecan IV over 30 minutes on days 1-5 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT and/or MRI throughout the study, tumor biopsy at screening and on study, and collection of blood samples at screening.

After completion of study treatment, patients are followed every 2 months for up to 6 months.

研究类型

介入性

注册 (实际的)

29

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Arizona
      • Phoenix、Arizona、美国、85054
        • Mayo Clinic Hospital in Arizona
    • California
      • Orange、California、美国、92868
        • UC Irvine Health/Chao Family Comprehensive Cancer Center
    • Connecticut
      • New Haven、Connecticut、美国、06520
        • Yale University
      • Trumbull、Connecticut、美国、06611
        • Smilow Cancer Hospital Care Center-Trumbull
    • Florida
      • Jacksonville、Florida、美国、32224-9980
        • Mayo Clinic in Florida
    • Kansas
      • Fairway、Kansas、美国、66205
        • University of Kansas Clinical Research Center
      • Kansas City、Kansas、美国、66160
        • University of Kansas Cancer Center
      • Overland Park、Kansas、美国、66210
        • University of Kansas Cancer Center-Overland Park
      • Overland Park、Kansas、美国、66211
        • University of Kansas Hospital-Indian Creek Campus
      • Westwood、Kansas、美国、66205
        • University of Kansas Hospital-Westwood Cancer Center
    • Minnesota
      • Rochester、Minnesota、美国、55905
        • Mayo Clinic in Rochester
    • Missouri
      • City of Saint Peters、Missouri、美国、63376
        • Siteman Cancer Center at Saint Peters Hospital
      • Creve Coeur、Missouri、美国、63141
        • Siteman Cancer Center at West County Hospital
      • Kansas City、Missouri、美国、64154
        • University of Kansas Cancer Center - North
      • Lee's Summit、Missouri、美国、64064
        • University of Kansas Cancer Center - Lee's Summit
      • North Kansas City、Missouri、美国、64116
        • University of Kansas Cancer Center at North Kansas City Hospital
      • St Louis、Missouri、美国、63110
        • Washington University School of Medicine
      • St Louis、Missouri、美国、63129
        • Siteman Cancer Center-South County
      • St Louis、Missouri、美国、63136
        • Siteman Cancer Center at Christian Hospital
    • New York
      • The Bronx、New York、美国、10461
        • Montefiore Medical Center-Einstein Campus
    • Oklahoma
      • Oklahoma City、Oklahoma、美国、73104
        • University of Oklahoma Health Sciences Center
    • Pennsylvania
      • Pittsburgh、Pennsylvania、美国、15232
        • UPMC Hillman Cancer Center
    • Tennessee
      • Nashville、Tennessee、美国、37232
        • Vanderbilt University/Ingram Cancer Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • DOSE ESCALATION COHORTS: Patients must have a biopsy-proven solid tumor that is metastatic or unresectable and has progressed on at least one line of standard therapy
  • DOSE ESCALATION COHORTS: Patients must have a solid tumor for which irinotecan or topotecan is considered standard of care
  • DOSE EXPANSION COHORTS: Patients must have biopsy proven metastatic or unresectable small cell lung cancer (SCLC), poorly differentiated neuroendocrine carcinoma (PD-NEC) (any extrapulmonary neuroendocrine carcinoma with small cell or large cell histology) or pancreatic adenocarcinoma (PDA) and have progressed on at least one line of standard therapy
  • DOSE EXPANSION COHORTS: Patients must have at least one measurable lesion outside of the lesion to be biopsied
  • Patients must be able to swallow pills
  • Age >= 18 years. Because no dosing or adverse event data are currently available on the use of BAY 1895344 in combination with irinotecan or topotecan in patients < 18 years of age, children are excluded from this study
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
  • Hemoglobin > 9 g/dL
  • Absolute neutrophil count >= 1,500/mcL
  • Platelets >= 100,000/mcL
  • Total bilirubin =< 2 x institutional upper limit of normal (ULN)
  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional ULN (=< 5 x institutional ULN if liver metastases present)
  • Glomerular filtration rate (GFR) >= 60 mL/min/1.73 m^2
  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression. Furthermore, these patients must be asymptomatic from previously treated brain metastases (e.g. not on steroids for neurologic symptoms within 30 days of study enrollment)
  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
  • The effects of BAY 1895344 on the developing human fetus are unknown. For this reason and because DNA-damage response inhibitors as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and for 6 months after completion of BAY 1895344 administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of BAY 1895344 administration
  • Patient must have the ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available will also be eligible

Exclusion Criteria:

  • Patients who have previously been treated with irinotecan will not be eligible to participate in the irinotecan arm and patients who have previously been treated with topotecan will not be eligible to participate in the topotecan arm. However, patients who previously received irinotecan may be treated with topotecan (and vice versa) should the other agent be considered a possible standard of care for their disease. Patients who have previously been treated with BAY 1895344 will be excluded from the study
  • Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia and endocrinopathies from prior immunotherapy
  • Patients who are receiving any other investigational agents
  • The investigator(s) must state a medical or scientific reason if patients who have brain metastases will be excluded from the study
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to BAY 1895344 or other agents used in study
  • Patients receiving any medications or substances that are substrates of CYP3A4 with a narrow therapeutic window, or strong inhibitors/inducers of CYP3A4 are ineligible, if they cannot be transferred to alternative medication. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
  • Patients with uncontrolled intercurrent illness
  • Patients with psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant women are excluded from this study because BAY 1895344 is agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with BAY 1895344, breastfeeding should be discontinued if the mother is treated with BAY 1895344. These potential risks may also apply to other agents used in this study
  • Patients with an uncontrolled infection requiring IV antibiotics will not be eligible to participate in the study
  • Patients on strong CYP3A4 inhibitors must discontinue them at least 1 week prior to starting irinotecan therapy

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Cohort I (elimusertib, irinotecan)

Patients receive elimusertib PO BID on days 1 and 2 and irinotecan IV over 90 minutes on day 1 of each cycle. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT and/or MRI throughout the study, tumor biopsy at screening and on study, and collection of blood samples at screening.

Undergo CT

其他名称:
  • CT
  • 猫
  • 电脑扫描
  • 计算机轴向断层扫描
  • 计算机断层扫描
  • CT扫描
  • 断层扫描
  • 计算机轴向断层扫描(程序)
  • 计算机断层扫描 (CT) 扫描
  • 诊断猫扫描
  • 诊断猫扫描服务类型

Undergo MRI

其他名称:
  • 核磁共振
  • 磁共振
  • 磁共振成像扫描
  • 医学影像、磁共振/核磁共振
  • 先生
  • 磁共振成像
  • 核磁共振成像扫描
  • 核磁共振成像
  • 磁共振成像 (MRI)
  • 磁共振成像(程序)
  • 结构核磁共振

Undergo collection of blood samples

其他名称:
  • 生物样本采集
  • 收集的生物样本
  • 标本采集
  • 样本收集

Undergo tumor biopsy

其他名称:
  • Bx
  • 活组织检查类型
  • 活检

Given IV

其他名称:
  • 坎普托
  • 坎普托沙
  • U-101440E
  • CPT-11
  • 喜树碱11
  • 第 11 期
  • 伊立美达
  • 盐酸伊立替康三水合物
  • 伊立替康单盐酸盐三水合物
  • CPT11
  • U 101440E
  • U101440E

Given PO

其他名称:
  • ATR 抑制剂 BAY1895344
  • ATR 激酶抑制剂 BAY1895344
  • 湾 1895344
  • BAY-1895344
  • BAY1895344
实验性的:Cohort II (elimusertib, irinotecan)

Patients receive elimusertib PO QD on days 2, 3, 9, 10, 16, and 17 of cycle 1 and 2, and on days 2, 3, 9, and 10 of each cycle thereafter. Patients receive irinotecan IV over 90 minutes on days 1, 8, and 15 of cycle 1 and 2, and on days 1 and 8 of each cycle thereafter. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT and/or MRI throughout the study, tumor biopsy at screening and on study, and collection of blood samples at screening.

Undergo CT

其他名称:
  • CT
  • 猫
  • 电脑扫描
  • 计算机轴向断层扫描
  • 计算机断层扫描
  • CT扫描
  • 断层扫描
  • 计算机轴向断层扫描(程序)
  • 计算机断层扫描 (CT) 扫描
  • 诊断猫扫描
  • 诊断猫扫描服务类型

Undergo MRI

其他名称:
  • 核磁共振
  • 磁共振
  • 磁共振成像扫描
  • 医学影像、磁共振/核磁共振
  • 先生
  • 磁共振成像
  • 核磁共振成像扫描
  • 核磁共振成像
  • 磁共振成像 (MRI)
  • 磁共振成像(程序)
  • 结构核磁共振

Undergo collection of blood samples

其他名称:
  • 生物样本采集
  • 收集的生物样本
  • 标本采集
  • 样本收集

Undergo tumor biopsy

其他名称:
  • Bx
  • 活组织检查类型
  • 活检

Given IV

其他名称:
  • 坎普托
  • 坎普托沙
  • U-101440E
  • CPT-11
  • 喜树碱11
  • 第 11 期
  • 伊立美达
  • 盐酸伊立替康三水合物
  • 伊立替康单盐酸盐三水合物
  • CPT11
  • U 101440E
  • U101440E

Given PO

其他名称:
  • ATR 抑制剂 BAY1895344
  • ATR 激酶抑制剂 BAY1895344
  • 湾 1895344
  • BAY-1895344
  • BAY1895344
实验性的:Cohort III (elimusertib, topotecan)

Patients receive elimusertib PO QD on days 2 and 5 and topotecan IV over 30 minutes on days 1-5 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT and/or MRI throughout the study, tumor biopsy at screening and on study, and collection of blood samples at screening.

Undergo CT

其他名称:
  • CT
  • 猫
  • 电脑扫描
  • 计算机轴向断层扫描
  • 计算机断层扫描
  • CT扫描
  • 断层扫描
  • 计算机轴向断层扫描(程序)
  • 计算机断层扫描 (CT) 扫描
  • 诊断猫扫描
  • 诊断猫扫描服务类型

Undergo MRI

其他名称:
  • 核磁共振
  • 磁共振
  • 磁共振成像扫描
  • 医学影像、磁共振/核磁共振
  • 先生
  • 磁共振成像
  • 核磁共振成像扫描
  • 核磁共振成像
  • 磁共振成像 (MRI)
  • 磁共振成像(程序)
  • 结构核磁共振

Undergo collection of blood samples

其他名称:
  • 生物样本采集
  • 收集的生物样本
  • 标本采集
  • 样本收集

Undergo tumor biopsy

其他名称:
  • Bx
  • 活组织检查类型
  • 活检

Given IV

其他名称:
  • 海康定
  • 苯丙胺
  • 斯凯孚 S-104864-A
  • 拓扑替康盐酸盐
  • 盐酸拓扑替康(口服)
  • 钾溶胶
  • 埃沃托平
  • 拓扑泰克
  • 盐酸诺吉替康
  • SKF S 104864 A
  • SKF S104864A

Given PO

其他名称:
  • ATR 抑制剂 BAY1895344
  • ATR 激酶抑制剂 BAY1895344
  • 湾 1895344
  • BAY-1895344
  • BAY1895344

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Maximum Tolerated Dose (MTD) (Dose Escalation Phase) of Elimursertib
大体时间:Up to 21 days (first treatment cycle)

Defined by occurrence of >= 2 dose limiting toxicities (DLTs) defined as grade 4 neutropenia lasting >= 7 days, grade 4 thrombocytopenia, grade 4 anemia, grade 3 neutropenia with fever, grade 3 thrombocytopenia with bleeding, any grade 3 hematologic toxicity lasting >= 7 days (counting from first day of toxicity grade recognition) or any non-hematologic grade >= 2 adverse events (AEs) lasting >= 7 days (with the exception of grade 2 [G2] fatigue, G2 nausea or G2 diarrhea) (counting from first day of toxicity grade recognition) in any dose level during cycle 1 of treatment. DLTs will be graded by Common Terminology Criteria for Adverse Events version 5.0.

Up to 21 days (first treatment cycle)
Maximum Tolerated Dose (MTD) (Dose Escalation Phase) of Irinotecan
大体时间:Up to 21 days (first treatment cycle)

Defined by occurrence of >= 2 dose limiting toxicities (DLTs) defined as grade 4 neutropenia lasting >= 7 days, grade 4 thrombocytopenia, grade 4 anemia, grade 3 neutropenia with fever, grade 3 thrombocytopenia with bleeding, any grade 3 hematologic toxicity lasting >= 7 days (counting from first day of toxicity grade recognition) or any non-hematologic grade >= 2 adverse events (AEs) lasting >= 7 days (with the exception of grade 2 [G2] fatigue, G2 nausea or G2 diarrhea) (counting from first day of toxicity grade recognition) in any dose level during cycle 1 of treatment. DLTs will be graded by Common Terminology Criteria for Adverse Events version 5.0.

Up to 21 days (first treatment cycle)
Maximum Tolerated Dose (MTD) (Dose Escalation Phase) of Topotecan
大体时间:Up to 21 days (first treatment cycle)

Defined by occurrence of >= 2 dose limiting toxicities (DLTs) defined as grade 4 neutropenia lasting >= 7 days, grade 4 thrombocytopenia, grade 4 anemia, grade 3 neutropenia with fever, grade 3 thrombocytopenia with bleeding, any grade 3 hematologic toxicity lasting >= 7 days (counting from first day of toxicity grade recognition) or any non-hematologic grade >= 2 adverse events (AEs) lasting >= 7 days (with the exception of grade 2 [G2] fatigue, G2 nausea or G2 diarrhea) (counting from first day of toxicity grade recognition) in any dose level during cycle 1 of treatment. DLTs will be graded by Common Terminology Criteria for Adverse Events version 5.0.

Up to 21 days (first treatment cycle)
Occurrence of Grade 4 Hematologic AEs (Dose Expansion Phase)
大体时间:Up to 6 months post-treatment

Grade 4 hematologic toxicity will be monitored using the Bayesian approach of Thall, Simon, Estey as extended by Thall and Sung. Clinical safety data (e.g. AEs) will be tabulated and summarized using descriptive statistics as requested by the sponsor investigator, executive committee, medical monitor or Data Safety Monitoring Board using methods described in the Data Safety Monitoring Plan.

Up to 6 months post-treatment

次要结果测量

结果测量
措施说明
大体时间
Objective Response Rate (ORR)
大体时间:Tumor response was performed every 6 weeks during treatment and up to 6 months after completing treatment

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT and/or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response Rate (ORR) = CR + PR.

Tumor response was performed every 6 weeks during treatment and up to 6 months after completing treatment
Duration of Response (DOR)
大体时间:Response was assessed every 6 weeks while the patient was on treatment, and up to 6 months post-treatment.

DOR will be estimated by the Kaplan-Meier method. Duration of response was calculated among patients with complete response, partial response, or stable disease.

Response was assessed every 6 weeks while the patient was on treatment, and up to 6 months post-treatment.
Progression-free Survival (PFS)
大体时间:Disease Progression was assessed every 6 weeks while the patient was on treatment, and up to 6 months post-treatment.

PFS will be estimated by the Kaplan-Meier method.

Disease Progression was assessed every 6 weeks while the patient was on treatment, and up to 6 months post-treatment.
Overall Survival (OS)
大体时间:From date the participant starts treatment until the date of death from any cause, assessed up to 6 months following completion of treatment

OS will be estimated by the Kaplan-Meier method.

From date the participant starts treatment until the date of death from any cause, assessed up to 6 months following completion of treatment
Maximum Concentration (Cmax) of Elimusertib
大体时间:See above as time frames were different fore each dose cohort

Estimated for elimusertib based upon plasma collections from cycle 1 in all study patients.

TACs 1,2: Before treatment, 30 min, 1h, 1.3h, 2h, 4h, 6h, 8h, 24h, and 48 h after first elimusertib dose; TACs 4,5: on Cycle 1 Day 1 Before treatment, 30 min, 1h, and 1.3h into infusion and 0.5h, 2.5h, 4.5h and 22h post end of infusion and Day 2 30 min, 1h, 1.3, 2h, 4h, 6h, 8h, 24h after the first elimursertib dose; TACs 7,14: cycle 1 day 1 and 2 before infusion, 5, 15, and 25 min into infusion, and 5, 15, 30 min, 1, 2, 4, 6, and 24 h post end of infusion

See above as time frames were different fore each dose cohort
Area Under the Concentration-time Curve (AUC) for Elimusertib
大体时间:See above as time frames are different for each dose cohort

Will be estimated for elimusertib based upon plasma collections from cycle 1 in all study patients.

TACs 1,2: Before treatment, 30 min, 1h, 1.3h, 2h, 4h, 6h, 8h, 24h, and 48 h after first elimusertib dose; TACs 4,5: on Cycle 1 Day 1 Before treatment, 30 min, 1h, and 1.3h into infusion and 0.5h, 2.5h, 4.5h and 22h post end of infusion and Day 2 30 min, 1h, 1.3, 2h, 4h, 6h, 8h, 24h after the first elimursertib dose; TACs 7,14: cycle 1 day 1 and 2 before infusion, 5, 15, and 25 min into infusion, and 5, 15, 30 min, 1, 2, 4, 6, and 24 h post end of infusion

See above as time frames are different for each dose cohort
Maximum Concentration (Cmax) of Irinotecan (Cohorts I and II)
大体时间:See above as time frames were different for each cohort

Estimated for irinotecan based upon plasma collections from cycle 1 in all study patients.

TACs 1,2: Before treatment, 30 min, 1h, 1.3h, 2h, 4h, 6h, 8h, 24h, and 48 h after first elimusertib dose; TACs 4,5: on Cycle 1 Day 1 Before treatment, 30 min, 1h, and 1.3h into infusion and 0.5h, 2.5h, 4.5h and 22h post end of infusion and Day 2 30 min, 1h, 1.3, 2h, 4h, 6h, 8h, 24h after the first elimursertib dose

See above as time frames were different for each cohort
Area Under the Concentration-time Curve (AUC) for Irinotecan
大体时间:See above as time frames were different for each cohort

Will be estimated for irinotecan based upon plasma collections from cycle 1 in all study patients.

TACs 1,2: Before treatment, 30 min, 1h, 1.3h, 2h, 4h, 6h, 8h, 24h, and 48 h after first elimusertib dose; TACs 4,5: on Cycle 1 Day 1 Before treatment, 30 min, 1h, and 1.3h into infusion and 0.5h, 2.5h, 4.5h and 22h post end of infusion and Day 2 30 min, 1h, 1.3, 2h, 4h, 6h, 8h, 24h after the first elimursertib dose

See above as time frames were different for each cohort
Maximum Concentration (Cmax) of Topotecan (Cohort III, TACs 7 and 14)
大体时间:Cycle 1 day 1 and 2 before infusion, 5, 15, and 25 min into infusion, and 5, 15, 30 min, 1, 2, 4, 6, and 24 h post end of infusion

Estimated for topotecan based upon plasma collections from cycle 1 in all study patients.

Cycle 1 day 1 and 2 before infusion, 5, 15, and 25 min into infusion, and 5, 15, 30 min, 1, 2, 4, 6, and 24 h post end of infusion
Area Under the Concentration-time Curve (AUC) for Topotecan
大体时间:Cycle 1

Will be estimated for topotecan based upon plasma collections from cycle 1 in all study patients.

Cycle 1
Changes in Tumor Expression Patterns of Gamma-H2AX
大体时间:Baseline up to cycle 1, day 6

Will be estimated for expansion cohort only study patients.

Baseline up to cycle 1, day 6
Changes in Tumor Expression Patterns of pS343-NBS1
大体时间:Baseline up to cycle 1, day 6

Will be estimated for expansion cohort only study patients.

Baseline up to cycle 1, day 6

其他结果措施

结果测量
措施说明
大体时间
Tumor ATM Expression Loss
大体时间:Baseline

Will assess the prevalence of tumor ATM expression loss in all patients. Will also estimate response outcomes (ORR, PFS, OS, DOR) in study patients by tumor ATM expression loss.

Baseline
Tumor Deoxyribonucleic Acid Damage Response (DDR) Gene Mutations Present
大体时间:Baseline

Will assess the specific tumor DDR gene mutations present in study patients. Will also estimate response outcomes (ORR, PFS, OS, DOR) in study patients with tumors with DDR gene mutations.

Baseline

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Thatcher Heumann、Yale University Cancer Center LAO

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年10月20日

初级完成 (实际的)

2025年2月15日

研究完成 (估计的)

2027年3月4日

研究注册日期

首次提交

2020年8月14日

首先提交符合 QC 标准的

2020年8月14日

首次发布 (实际的)

2020年8月17日

研究记录更新

最后更新发布 (实际的)

2026年11月13日

上次提交的符合 QC 标准的更新

2026年11月11日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅